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This report offers descriptive data about the drugs 
utilized in office practice in the calendar year 1981, 
highlighting those pharmaceutical agents that were most 
frequently ordered or provided. The data, based on the 
findings of the National Ambulatory Medical Care Sur­
vey (NAMCS), were produced by a representative sam-
Ie of the Nation’s physicians who are primarily engaged 
1ofllce-based, patient-care practice. Non-Federal doc-
tors of medicine and osteopathy in all states except 
Alaska and Hawaii participated by completing records 
(figure 1, Patient Record) on a sample of their office 
visits over a weekly reporting period. 
Item 11 of the Patient Record (figure 1) requires that 
the respondents report the names of the specific drugs 
that they “utilized” (that is, ordered or provided) in the 
course of their office visits. This resulted in an estimated 
651,153,000 drug mentions. All routes of administration 
were allowed, and the mentions included immunizing 
and desensitizing agents, and nonprescription as well as 
prescription drugs. The physician recorded all new drugs 
and continued medications when the patient was specif­
ically instructed during the visit to continue the medica­
tion. Drugs ordered through telephone contact were not 
included. 
Because the estimates presented here are based on a 
sample rather than on the entire universe of office visits, 
the data are subject to sampling variability. Because of 
problems with statistical significance, the data user 
should avoid too literal an acceptance of closely ranked 
estimates. The technical notes at the end of this report 
provide a brief explanation of the sampling errors and 
idelines for judging the precision of estimates. All 
ubsequent references to drug mentions should be inter­
preted as estimated drug mentions, based on the sample 
of office-based physicians used in this study. 
of Health Care Statistics 
The 100 drug entries that respondents most frequently 
recorded are listed in rank order in table 1. The listing is 
arbitrarily restricted to the drugs that were specifically 
named—either by brandl or by generic name. This led 
to the exclusion of two entry choices that did not identify 
a specific agen~ indicating only the therapeutic effect 
desired. These two therapeutic effects were 
�	 Allergy relief ordzots( unspecified), with 10,833,000 
mentions. 
� Vihmru%(s)(unspecified), with 1,520,000 mentions. 
The 100 drugs comprise only 4 percent of the 2,325 
agents named by respondents. However, they account 
for about 341,427,000 mentions, or 52 percent of the 
total 651,153,000 drug mentions. 
The 11 drugs most frequently named in 1981 were 
also the leading 11 in 1980. The rank order of the 
specific drugs, however, varied somewhat between the 
years (table 2). The two most notable gains in rank 
position were registered by Inderal, a beta-adrenergic 
blocking agent, and Dyazide, a diuretic agent. 
In table 3, drug utilization in 1981 is expressed 
entirely in generic terms. Listed in alphabetical order 
are the 100 generic substances most frequeiitly ordered 
or provided, either in single-entity form or as ingredients 
of combination products. Thus, the 29,687,000 total 
mentions of the ranking generic substance, hydrochlor~ 
thiazide, include its 11,583,000 mentions as a single-
entity drug and its 18,105,000 mentions as an active 
component of a combination drug. 
1Inclu5ionoftiade names is for identification only and does not imply endorse­
ment by the Public Health Service or the U.S. Department of Health and 
Human Services. 
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Another usefil overview of 1981 drug utilization 
appears in table 4. Here the651, 153,000 ~g mentions 
are described by the chief therapeutic effect that each 
was intended to produce. A comprehensive listing of 67 
therapeutic categories is used. (The categories were 
selected from the American Hospital Formulary Class­
tication System.z) The data user may note the obvious 
preeminence enjoyed by the nontropical anti-infective 
agents, the central nervous system drugs, and the com­
bination of cardiovascular drugs and diuretics used to 
2American Society of Hospital Pharmacists, Inc.: The ,Onericszn Hospital 
Formulary Classt#ication System Washington. Jan. 1980. 
combat circulatory disease. Together these three catego­
ries accounted for virtually one:half of all drug mentions. 
From 1980 to 1981, the use proportion (percent of 
all drug mentions) did not vary greatly for most of the 
therapeutic categories (table 5). The largest single de-
crease (0.6 percent) was registered by skin preparations. 
Their estimated number of mentions fell by about 6.2 
million in 1981. These findings directly parallel a 0.6 
percent drop found in 1981 for the number of office 
visits with skin disease as the principal diagnosis. Th 
largest single increase in use proportion ( 1.8 percentu 
was achieved by the combination of cardiovascular 
drugs and diuretics. Their estimated number of men­
tions rose by about 6.7 million in 1981. This increase 
admce&a3 
w“ 
appears directly related to the 0.7-percent increase found 
in 1981 for the number of ofilce visits with circulatory 
isease as the principal diagnosis. Also contributing to 
e increase was the sharp surge in popularity enjoyed 
by certain new cardiovascular drugs, especially the 
beta-adrenergic blocking agents. They are useful in 
treating hypertension, angina, cardiac arrhythmia, and 
in preventing the recurrence of myocardial infarction. 
Measured in terms of drug-visit proportion (that is, 
the percent of office visits at which one or more drugs 
were ordered or provided), the overall utilization of 
drugs by office-based physicians fell from 63.1 percent 
in 1980 to 60.5 percent in 1981, a decrease of 2.6 
percent. 
NAMCS drug findings for 1981 are reportable by 
product name, generic name, entry status (generic ver­
sus brand name), prescription status (prescription versus 
nonprescription), level of potential abuse (Federal con­
trol schedules), composition (single-ingredient versus

combination), and therapeutic effect. These drug dimen­

sions may be contrasted with other NAMCS variables

to show the influence on drug utilization produced by

prescriber characteristics, patient demographics, refer­

ral status, duration and disposition of the visit and by

such clinical features as symptoms, diagnosis, diagnos­

tic procedures, and other (nondrug) forms of treatment.
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Tablel. The 100 drugs most frequently ordered or provided in office practice by drug name (as recorded by the physician), number of mentions, and therapeutic use: 

























Name of drug 
All drugs,.,.,....,...,...,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Inderal (propranolol) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Lasix(furosemide) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Dyazide (triamterene, hydrochlorothiazide. . . . . . . . . . . . . . . . ., ., . . . . 
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Lanoxin (digoxin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Tetracycline, .,........,...,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Diphtheria tetanus toxoids pertussia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Polio vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Valium (diazepam) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Motrin (ibuprofen) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Etythromycin .,........,...,., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Prednisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
E. E. S.(erythromycin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ,., .,.,. 
Aldomet (methyldopa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Tagamet (cimetidine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Dioxin, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Hydrodiuril (hydrochlorothiazide) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Amoxil(amoxicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Hygroton [chlorthalidone) ..,....,. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Keflex(cephalexin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Oimetapp (brompheniremine, phenylephrine, phenylpropanolamine) . . . . . . . . . . . . 
Tylenol with codeine (acetaminophen, codeine). . . . . . . . . . . . . . . . . . . . . ., ., ., . 
Actifed (triprolidine, pseudoephedrine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Isordil (isosorbide) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Vitamin 8-12......,............,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Naprosyn (naproxen), . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Septra(sulfamethoxazole, trimethoprim) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Tuberculin tine test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8actrim (sulfamethoxazole, trimethoprim) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Clinoril (sulindac) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Tylenol (acetaminophen) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Lopresaor (metoprolol) ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Phenergan (promethazine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Indocin (indomethacin) ...,.,... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8enad@(diphenhydramine) .,... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Decadron (dexamethasone) ..,... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Nitroglycerin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Slow- K(potassium replacement solutions) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Zomax(zolamine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Diabinese (chlorpropamide) .,... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Pen-Vee K (penicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Premarin (estrogens) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Depo-medrol (methylprednisolone). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Kenalog (triamcinolone) . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Donnatal (hyosciamine, atropine, hyoscine, phenobarbital) . . . . . . . . . . . . . . . . 
Influenza virus vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Coumadin (warfarin). .,........,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Ceclor(cefaclor) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Neosporin (polymixin-B, neomycin).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Synthroid (levothyroxine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Dimetane (brompheniramine) .,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
E-mycin (erythromycin) ..,.,.... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Aldoril (methyldopa, hydrochlorothiazide) . . ., ., ., . . . . . . . . . . . . . . . . . . . . . . . 
Bicillin (penicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Xylocaine (lidocaine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8utazolidin [phenylbutazone) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Naldecon (phenylephrine, phenylpropanolamine, chlorpheniramine) . . . . . 
Darvocet-N (propoxyphene, acetaminophen), . . . . . . . . . . . . . . . . . . . . ., . . . 
Mylanta (magnesium hydroxide, aluminum hydroxide) . . . ., . . . . . 
Antivett (meclizine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 














































































































































































































Table 1. The 100 drugs most frequently ordered or provided in office practice by drug name (as recorded by the physician), number of mentions, and therapeutic use 
United States. 1981 —Con, 
Number 
R
* of a 






67 Dilantin (phenytoin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,054 Anticonvulsant 
68 Empirin with codeine (aspirin, codeine). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,042 Analgesic, antipyretic 
69 Dalmane (flurazepam) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,041 Hypnotic 
70 Cleocin (clindamycin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,033 Antibiotic 
71 Potassium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,028 Potassium replacement therapy 
72 Theo-dur(theophy nine). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,026 Coronary vasodilator, diuretic 
73 Cortisporin (polymixin-B, bacitracin, neomycin, hydrocortisone) . . . . . . . . . . . . . . . . 1,979 Anti-inflammatory 
74 Phenergan with codeine (promethazine, codeine) . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,97B Expectorant 
75 Vibramycin (doxycycline) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,957 Antibiotic 
76 V-cillin (penicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,946 Antibiotic 
77 Persantine (dipyridamole) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,932 Coronay or myocardial insufficiency 
78 Rondec (pseudoephedrine, carbinoxamine maleate). . . . . . . . . . . . . . . . . . . . . . . . . . 1,928 Decongestant, antitussive 
79 T[moptic (timolol) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,914 Treatment of glaucoma, ocular hypertension 
80 Prenatal vitamins (multivitamins prenatal). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,873 Vitamins 
81 Minipress (prazosin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,789 Antihypertensive 
82 Aldactazide (spironolactone, hydrochlorothiazide) . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,788 Antihypertensive 
83 Aristocort (triamcinolone) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,766 Anti-inflammatory 
84 Monistat [miconazole) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,743 Antifungal 
85 Phenobarbital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,694 Anticonvulsant, sedative, hypnotic 
86 llosone (e~thromycin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,692 Antibiotic 
87 Larotid (amoxicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,640 Antibiotic 
88 Librax (clidinium bromide, chlordiazepoxide) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,635 Gastro-intestinal disorders 
89 Robitussin (guaifenesin, dextromethorphan, phenylpropanolamine) . . . . . . . . . . . . . 1,633 Antitussive, decongestant, expectorant 
90 Sudafed (pseudoephedrine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,604 Decongestant 
91 Tuss-ornade (chlorpheniramine, phenylpropanolamine). . . . . . . . . . . . . . . . . . . . . . 1,580 Antitussive, decongestant 
92 Ativan(lorazepam) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,579 Psychotherapeutic agent 
93 Librium (chlordiazepoxide) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,569 Psychotherapeutic agent 
94 Flexeril (cyclobenzaprine] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,568 Skeletal muscle relaxant 
95 Zylopnm (allopunnol} . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,567 Antigout 
96 Dnxoral (bromphenwamme, pseudoephedrine) . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,561 Decongestant, antihistamine 
97 Corgard (nadolol] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.550 Antihypertensive, beta-blocker 
98 Celestone (betamethasone) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,544 G[ucocorticoid 
99 Parafon forte (chlorzokazone, acetammophen) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,528 Skeletal muscle relaxant 
100 Ortho-novum (norethmdrone, estradiol). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,519 Oral contraceptive 
Table 2. The 11 drugs most frequently named in 1980 and 1981 by frequency of mention and rank ordec United States, 1981 
Number of 
mentions Rank 
Name of drug in thousands 
1987 1980 1981 1980 
11,847 9,625 1 4 
10,770 9,879 2 1 
10,422 7,435 3 7 
9,173 9,795 4 2 
8,581 9,736 5 3 
7,543 8,800 6 6 
7,311 7,105 7 8 
7,030 9,478 8 5 
6,583 6,067 9 11 
6,237 6,535 0 9 
Valium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,063 6,499 11 10 
6 acklncechta 






















































































































Estrogen replacement therapy 






























































Phenobarbital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,011 34 Anticonvulsant, sedative, hypnotic 
Phenylbutazone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,742 92 Anti-inflammatory 
Phenylephrine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,140 6 Sympathomimetic 
Phenylpropanolamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16,455 5 Sympathomimetic 
Phenyltoloxamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,037 81 Antihistaminic 
Polio vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,248 31 Immunization 
Polymixin B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,259 30 Antibacterial 
Potassium guaiacolsulfonate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,868 63 Cough preparations 
Potassium replacement solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,665 22 Potassium replacement therapy 
Prednisolone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,778 66 Anti-inflammatory 
Prednisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,706 40 Anti-inflammatory 
Promethazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,939 37 Antihistaminic, anti-emetic, sedative 
Propoxyphene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,551 68 Analgesic 
Propranolol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,813 8 Beta-blocker 
Pseudoephedrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,933 7 Antihistaminic, cough suppressant 
Reserpine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,204 55 Antihypertensive 
Salicylic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,126 99 Antifungal, keratolytic 
Scopolamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,528 69 Hypnotic, sedative, anticholinergic 
Simethicone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ,. 2,926 84 Antiflatulent 
Spironolactone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,826 89 Diuretic 
Sulfacetamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,258 77 Antibacterial 
Sulfamethoxazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,393 24 Antibacterial 
Sulindac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,318 75 Analgesic, antipyretic 
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,316 16 Antibiotic 
Theophylline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,647 27 Coronary vasodilator, diuretic 
Triamcinolone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,616 28 Anti-inflammatory 
Triamterene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,681 15 Diuretic 
Trimethoprim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,150 25 Antibacterial 
Triprolidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,647 54 Antihistaminic 
Tuberculin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.423 71 Tuberculosis skin test 
Vitamin B-12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ., 5,137 48 Vitamins 
Warfarin 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
2,536 95 Anticoagulant 
Zinc topical agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,805 65 Skin disease (astringent, antiseptic) 
Zolamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,872 88 Antihistaminic, local anesthetic 
lc~~binesthemention$of agenericsubstsnce as asmgle-ingredient agent wnthits mentnons as an mgred!entof a combination dreg. 
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Table4. Number andpercent distribution ofdrugmentions byselected therapeutic categories United States, l98l 
Number Number 
of Percent of Percent 
Selected therapeutic categories mentions distri- Selected therapeutic categories mentions distri- 0 
in bution in bution 
thousands thousands 
All categories..............,., . . . . . . . . . . . 651,153 100.0 Eye, ear, noae, andthroat preparations—Con. 
Anti-inflammatory agents. . . . . . . . . . . . . . . . . . 4,772 0.73 
Antihistami ne drugs . . . . . . . . . . . . . . . . . . . 43,511 6,68 Local anesthetica . . . . . . . . . . . . . . . 1,947 0.30 
Anti-infective agents . . . . . . . . . . . . 104,804 16.10 Miotics . . . . . . . . . . . . . . . . . . . . . . . . 1,590 0.24 
Anti biotics . . . . . . . . . . . . . . . . . . 89,209 13.70 Mydriatics . . . . . . . . . . . . . . . . . . . . . . . 1,666 0.26 
Cephalosporins . . . . . . . . . . . . . . . . 8,355 1.28 Vaaoconstrictora . . . . . . . . . . . . . . . . . 2,004 0.31 
Erythromycins . . . . . . . . . . . . . . . . . 16,119 2.48 Gastrointestinal drugs . . . . . . . . . . . . . . . . . . . . . 24,196 3.72 
Penicillins . . . . . . . . . . . . . . . . . . . . . . . 41,524 6.38 Antacids andadsorbents . . . . . . . . . . . . . . . . . . 3,562 0.55 
Tetracycline . . . . . . . . . . . . . . . . . . 15,010 2.31 Antidiarrhea agents. . . . . . . . . . . . . . . 3,324 0.51 
Sulfonamides . . . . . . . . . . . . . . . . . . . . . . 9,236 1.42 Antiflatulenta . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,947 0.45 
Antineoplastic agents . . . . . . . . . . . 4,019 0.62 Cathartica and laxatives . . . . . . . . . . . . . . . . . . . 3,655 0.56 
Autonomic drugs . . . . . . . . . . . . . . . 24,102 3,7’0 Emetics and anti- emetics . . . . . . . . . . . . . . . 3,776 0.58 
Paraaympatholytic agents . . . . . . . . . . . . . . . . 9,574 1.47 Hormones and synthetic substances. . . . . . . . . . 53,999 8.29 
Skeletal muscle relaxants . . . . . . . . . . . . . . . . 5,737 0.88 Adrenals . . . . . . . . . . . . . . . . . . . . . . . . . . . 20,731 3.18 
Sympathomimetic agenta. 7,235 1.11 Contraceptives . . . . . . . . . . . . . . . . . 6,141 0.94 
Blood formation and coagulation. . 8,020 1.23 Estrogens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,877 1,06 
Anti-anemia druga . . . . . . . . . . . . . . 5,325 0.82 Insulina andantidiabetic agents . . . . . . . . . . . . 10,901 1.67 
Anticoagulants . . . . . . . . . . . . . . . . . . . 2,675 0.41 Insulins . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,314 0.82 
Cardiovascular drugs, ., .,.,...., . . . . . . . . . . 68,779 0.56 Thyroid and antithyroid . . . . . . . . . . . . . . . . . 4,328 0.66 
Cardiac druga . . . . . . . . . . . . . . . . . . . . . . . . . . 30,184 4.64 Serums, toxoids, and vaccines. . . . . . . . . . . . . . . . . . 22,068 3.39 
Hypotenaive agents, .,....... 24,263 3.73 Toxoids, . . . . . . . . . . . . . . . . . . . . . . . . . . 8,813 1.35 
Vasodilating agents, . . . . . . . . . . . 13,730 2.11 Vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,655 1.94 
Central nervoua aystem drugs, . . . . . . . . . . . 104,391 6.03 Skin andmucous membrane preparations . . . . . . . 49,026 7.53 
Analgesics and antipyretics. ., . . . . . . . . 58,841 9,04 Anti-i nfectives . . . . . . . . . . . . . . . . . . . . . . . . . 12,049 1.85 
Anticonvulsants . . . . . . . . . . . . . . . . 2,858 0.44 Fungicides . . . . . . . . . . . . . . . . . . . . . . . 4,781 0.73 
Antidepressants . . . . . . . . . . . . . . . . . . 9,892 1,52 Anti-i nflammatory agenta. . . . . . . . . . . . . . . . . . 17,463 2.68 
Respiratory andcerebral stimulants 4,501 0,69 Antipruritics and local anesthetics . . . . . . . . . 4,506 0.69 
Tranquilizers, sedatives, and hypnotics . . . . . 27,574 4,23 Emollients, protestants, demtdcents . . . . . . . . . 2,989 0.46 
Electrolytic, caloric, and water balance 
Diuretics . . . . . . . . . . . . . . . . . . . 
Replacement solutions . .,.,,,.,. 






Keratolytic agents . . . . . . . . . . 
Spasmolytic agents . . . . . . . . . .. . . . 













































Expectorants and cough preparationa. 17,864 2,74 Multivitamin preparations. . . . . . . . . . . . . . . . . . 11,638 1.79 
Eye, ear, nose, andthroat preparationa. . . 23,546 3,62 Vitamin 8 complex . . . . . . . . . . . . . . . . . . . . . . . 5,939 0.91 
Anti-infective agenda, . . . . . . . . . . . . . . . . . . 6,330 0.97 Other agents or therapeutic categow 
Antibiotics . . . . . . . . . . . . . . . . . . . . . . . 3,830 0.59 undetermined . . . . . . . . . . . . . . . . . . . . . . . . . . . 16,393 2.52 
18aSedo" the PharmaCOlOgiC.ther~ peuticclsssificatio" of the American SOCietyOf H0Spi<al Pharmacists, inc.; selected categories reproduced tvithpermissi0n. 
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Table 5. UsepropoRion ofselected therapeutic categories ofdrugs utilized inofice practice in1980and 1981: United States, 1981 
Selected therapeutic catego# 
0 
All categories . . . . . . . . . . . . . . . . . . . . . 
All categories . . . . . . . . . . . . . . . . . . . . . 
Adrenals . . . . . . . . . . . . . . . . . . . . . . 
Analgesia and antipyretics . . . . . . . . . . 
Antidepressants . . . . . . . . . . . . . . . . . . . 
Antihistamine drugs . . . . . . . . . . . . . . . . 
Anti-infective agents. . . . . . . . . . . . . . . . 
Antineoplastic agents. . . . . . . . . . . . . . . 
Autonomic drugs . . . . . . . . . . . . . . . . . . . 
Blood formation and coagulation. . . . . . 
Cardiovascular drugs and diuretics . . . . 
Use proportion 
198? 7980 














Selected therapeutic categoryl 
1981 1980 
Contraceptives . . . . . . . . . . . . . . . . . . . . 
Expectorants and cough 
preparations . . . . . . . . . . . . . . . . . . . . 
Eye, ear, nose, and throat 
preparations . . . . . . . . . . . . . . . . . . . 
Gastrointestinal drugs . . . . . . . . . . . . . . 
Serums, toxoids, and vaccines. . . . . . . . 
Skin and mucous membrane 
preparations . . . . . . . . . . . . . . . . . . . . 
Spasmolytic agents . . . . . . . . . . . . . . . . . 
Tranquilizers, sedatives, hypnotics . . . . 
Vitamins . . . . . . . . . . . . . . . . . . . . . . . . . 
Other agents or therapeutic catego~ 












1Basedon the pharmacologic-therapeuticclassification of the American Society of Hospital Pharmacists, Inc.; selected categories reproducedwith Permission. 
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Technical notes 
Source of data and sample design 
The estimates presented in this report are based on 
data collected during 1981 by the National Center for 
Health Statistics by means of the National Ambulatory 
Medical Care Survey (NAMCS). The target universe 
of NAMCS comprises office visits made by ambulatory 
patients to non-Federal physicians who are principally 
engaged in office-based, patient-care practice. Visits to 
physicians practicing in Alaska and Hawaii are excluded 
from the range of NAMCS, as are visits to physicians 
who specialize in anesthesiology, pathology, and radiol­
ogy. 
NAMCS uses a multistage probability sample design 
that involves a stepwise sampling of primary sampling 
units (PSU’S), physicians’ practices within PSU’S, and 
patient visits within physicians’ practices. For 1981 a 
sample of 2,846 physicians was selected from master 
files maintained by the American Medical Association 
and the American Osteopathic Association. The phy­
sician response rate was 77.5 percent. Sampled physi­
cians were asked to complete Patient Records (figure 1) 
for a systematic random sample of office visits made 
during a randomly assigned weekly reporting period. 
Telephone contacts were excluded. During 1981, re­
sponding physicians completed 43,366 Patient Records, 
on which they recorded 46,424 drug mentions. Char­
acteristics of the physician’s practice, such as primary 
specialty and type of practice, were obtained during an 
induction interview. The National Opinion Research 
Center, under contract to the National Center for Health 
Statistics, was responsible for the field operations of the 
survey. 
Sampling errors and rounding of 
numbers 
The standard error is primarily a measure of the 
sampling variability that occurs by chance because only 
a sample, rather than the entire universe, is surveyed. 
* The r;lative standard error of an estimate is obtained by 
dividing the standard error by the estimate itself and is 
expressed as a percent of the estimate. Relative stand­
ard errors of selected aggregate visit statistics are shown 
in table I. Standard errors for estimated percents of 
visits are shown in table II. Similar standard errors for 
drug statistics and percents are shown in tables 111and 
IV. Tables I and II should be used to obtain the standard 
error of a specific drug mention (for example, Dyazide). 
Tables III and IV should be used to obtain the standard 
error of a group of drug mentions (for example, all anti­
biotics). 
Estimates of office visits have been rounded to the 
nearest thousand. For this reason detailed figures within 
tables do not always add to totals. Rates and percents 
were calculated on the basis of original, unrounded 
figures and will not necessarily agree precisely with 
percents calculated from rounded data. 
Table 1. Approximate relative standard errors of estimated number of office 
visits based on all physician specialties NAMCS, 1981 
Relative 
Estimated number of office visits standard 











Example of use of table: An aggregate estimate of 75,000,000 visits has a relative 
standard error of 4.7 percent, or a standard error of 3,525,000 visits (4,7 percent of 
75,000,000). 
Table Il. Approximate standard errors of percents of estimated numbers of office visits based on all physician specialties NAMCS, 1981 
Estimated percent
Base of percent 
(number of office visits in thousands) 
7 or 99 5 or 95 10 or90 20 or 80 30 or 70 50 
Standard error in percent 
500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 5.9 8.1 10.8 12.4 13.5 
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.2 5.7 7.6 8.7 9.5 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.3 2.9 4.0 5.4 6.2 6.7 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.8 1.9 2.6 3.4 3.9 4.3 
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 1.8 2.4 2.8 3.0 
20.000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . 
. 


















500,000 . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 0.3 0.3 0.4 0.4 




Table Ill. Approximate relative standard errors of estimated number of drug 
.-
mentions based on all physician specialties NAMCS, 1981 
Relative 
r 
Estimated number of drug mentions standard 











Example of use of table: An aggregate esttmate of 75,000,000 drug mentions has a rela­
tive standard error of 6.5 percent, ora standard error of4,875,000 mentions (6.5 percent 
of 75,000,000). 
Definitions of terms 
An ambzdatorypatientis an individual seeking per­
sonal health services who is neither bedridden nor cur­
rently admitted to any health care institution on the 
premises. 
A physician eIigibleforNAMCS is a duly licensed 
doctor of medicine (M.D.) ordoctorof osteopathy (D. O.) 
currently in office-based practice who spends time in 
caring for ambulato~ patients. Excluded from NAMCS 
are physicians who are hospital base@ physicians who 
specialize in anesthesiology, pathology, or radiology; 
physicians who are federally employed physicians who 
treat only institutionalized patien~, physicians employed 
full time by an institutio~ and physicians who spend no 
time seeing ambulatory patients. 
An ofice is a place that physicians identify as a 
location for ambulatory practice. Responsibility over 
time for patient care and professional services rendered 
there generally resides with the individual physician rather 
than with an institution. 
A visit is a direct personal exchange between an 
ambulatory patient and a physician, or a staff member 
working under the physician’s supervision, for the pur­
pose of seeking care and rendering health services. 
A drug mention is the physician’s entry of a phar­
maceutical agent ordered or provided—by any route of 
administration-for prevention, diagnosis, or treatment. 
Generic as well as brand-name drugs are included, as 
are nonprescription as well as prescription drugs. The 
physician records all new drugs and continued medica­
tions when the patient is specifically instructed during 
the visit to continue the medication. 
Table W. Approximate standard errors of percents of estimated numbers of drug mentions based on all physician specialties NAMCS, 1981 
Base of percent 
Estimated percent 
(number of drug mentions in thousands) 
7 or 99 5 or 95 10 or 90 20 or 80 30 or 70 50 
Standard error in percent 
1,000................................................... 2.7 5.8 8.0 10.7 12.2 13.3 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.1 5.7 7.6 8.7 9.4 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.2 2.6 3.6 4.8 5.5 6.0 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 1.8 2.4 2.7 3.0 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.3 0.6 0.8 1.1 1.2 1.3 
600,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 0.3 0.4 0.5 0.5 
Example of use of table: An estimate of 30 percent based on an aggregate of 12,500,000 dmg mentions has a standard error of4.1 percent, ma relative standard error of 13.7 percent (4.1 
percent +30 percent]. 
12 ackincedata 
Recent Issues of Advance Data From Vital and Health Statistics 
No. 88. 1981 Summarw National Ambulatory Medical Care Sur­
vey (Issued March 16: 1983) 
No. 87. Drug Utilization in General and Family Practice by Char­
acteristics of Physicians and OffIce Visits: National Ambulatory 
Medical Care Survey, 1980 (Issued March 28, 1983) 
No. 86. Drug Utilization in Ofice Visits to Primary Care Physi­
cians: National Ambulatory Medical Care Survey, 1980 (Issued. 
October 8, 1982) 
SUGGESTED CITATION

National Center for Health Statistics, H. Koch:

Drugs most frequently used in office practice,

National Ambulatory Medical Care Survey, 1981.

Advance Data From Vital and Health Statistics,

No. 89, DHHS Pub. No. (PHS) 83-1250. Public

Health Service, Hyattsville, Md. April 1983,















PENALTY FOR PRIVATE USE, $300

To receive this publication regularly, contact the





DHHS Publication No. (PHS) 83–1250

No. 85. Summary Data From the National Inventory of Phar- 0 
macists: United States, 1978–79 (Issued October 8, 1982) 
No. 84. Blood Pressure Levels and Hypertension in Persons Ages 
6-74 Years: United States, 1976-80 (Issued 
COPYRIGHT INFORMATION 
This report may be reprinted 
permission. 
POSTAGE ANO FEES PAl O 




October 8, 1982) 
without further
*.

U.S.MAIL0°
